Halozyme Therapeutics (NASDAQ:HALO) Hits New 1-Year High – What’s Next?

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $66.00 and last traded at $64.02, with a volume of 2399504 shares. The stock had previously closed at $65.16.

Analyst Ratings Changes

A number of brokerages have weighed in on HALO. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Benchmark reiterated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Stock Down 1.7 %

The company has a market cap of $7.91 billion, a P/E ratio of 18.66, a P/E/G ratio of 0.42 and a beta of 1.32. The stock has a 50-day moving average of $58.39 and a two-hundred day moving average of $54.68. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock worth $1,754,451 in the last ninety days. 2.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in shares of Halozyme Therapeutics during the third quarter valued at approximately $217,000. Advisors Asset Management Inc. increased its position in Halozyme Therapeutics by 5.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 39,646 shares of the biopharmaceutical company’s stock valued at $2,269,000 after purchasing an additional 2,174 shares during the period. Centaurus Financial Inc. bought a new position in Halozyme Therapeutics in the 3rd quarter worth $127,000. Fisher Asset Management LLC lifted its position in shares of Halozyme Therapeutics by 6.8% in the 3rd quarter. Fisher Asset Management LLC now owns 324,005 shares of the biopharmaceutical company’s stock worth $18,546,000 after purchasing an additional 20,721 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $163,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.